Updated Reporting Guidance for Prescription Drug Price Transparency

On August 1, 2023, MDH released revised reporting guidance that addresses technical fixes to existing manufacturer reporting.

The updated reporting requirements apply to drugs with price increases and with introductions for sale in the United States that meet the reporting criteria beginning July 1, 2023.  Because the statute requires manufacturers to report to MDH no later than 60 days after the effective date of a new or increased price, the first reporting deadline under the updated guidance is August 30, 2023.

Updated Reporting Guidance (PDF)